Gilead Forms Kidney Disease Pact with Goldfinch Bio

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)

Published: 14 May-2019

DOI: 10.3833/pdr.v2019.i5.2423     ISSN: 1756-7874

Section: Research & Development



In a bid to strengthen its pipeline, Gilead has agreed to a multi-year collaboration with Goldfinch Bio to discover, develop and commercialise a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases using Goldfinch’s genetic and biologic platforms...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details